ABSTRACT G protein-coupled receptors (GPCRs) regulate virtually all aspects of human physiology and represent an important class of therapeutic drug targets. Many GPCR-targeted drugs resemble endogenous agonists, often resulting in poor selectivity among receptor subtypes and restricted pharmacologic profiles. The muscarinic acetylcholine receptor family exemplifies these problems; thousands of ligands are known, but few are receptor subtype-selective and nearly all are cationic in nature. Using structure-based docking against the M 2 and M 3 muscarinic receptors, we screened 3.1 million molecules for ligands with new physical properties, chemotypes, and receptor subtype selectivities. Of 19 docking-prioritized molecules tested against the M 2 subtype, 11 had substantial activity and 8 represented new chemotypes. Intriguingly, two were uncharged ligands with low micromolar to high nanomolar K i values, an observation with few precedents among aminergic GPCRs. To exploit a single amino-acid substitution among the binding pockets between the M 2 and M 3 receptors, we selected molecules predicted by docking to bind to the M 3 and but not the M 2 receptor. Of 16 molecules tested, 8 bound to the M 3 receptor. Whereas selectivity remained modest for most of these, one was a partial agonist at the M 3 receptor without measurable M 2 agonism. Consistent with this activity, this compound stimulated insulin release from a mouse b-cell line. These results support the ability of structure-based discovery to identify new ligands with unexplored chemotypes and physical properties, leading to new biologic functions, even in an area as heavily explored as muscarinic pharmacology.
Introduction
G protein-coupled receptors (GPCRs) are integral transmembrane proteins that transduce extracellular signals from neurotransmitters, hormones, odorants, and many other signals across cellular membranes. The muscarinic acetylcholine receptors (M 1 -M 5 ) are a subfamily of GPCRs recognizing the neurotransmitter acetylcholine and signaling through G proteins of the G q/11 class (M 1 , M 3 , and M 5 subtypes) and the G i/o class (M 2 and M 4 subtypes). These receptors are targets for the treatment of many illnesses, including chronic obstructive pulmonary disease, urinary incontinence, and diabetes , and have been implicated in treatment of cognitive disorders such as Alzheimer's disease (Messer, 2002) and schizophrenia (Chan et al., 2008) .
Tool and drug development at muscarinic receptors has been complicated by difficulties in finding subtype-selective ligands. None of the muscarinic agonists and antagonists currently used in the clinic are selective for a particular muscarinic receptor subtype. This reflects the high sequence identities among the orthosteric sites of the M 1 -M 5 receptors, differing, for instance, between the M 2 and M 3 subtypes by only a single residue. Muscarinic receptors can also mediate various side effects (e.g., adverse effects on heart rate, salivary secretion, and smooth muscle contractility). For example, whereas recent evidence suggests that an M 3 agonist would promote insulin release in type 2 diabetes , M 2 agonism would have substantial cardiac effects that would complicate clinical use. Similarly, M 1 agonists have shown promise for treatment of Alzheimer's disease, but dose-limiting side effects have precluded clinical use (Caccamo et al., 2009) . Consequently, recent attempts to develop selective muscarinic drugs have focused on ligands targeting either an allosteric site (Conn et al., 2009b) or both orthosteric and allosteric sites simultaneously (Mohr et al., 2010) .
The recent determination of the crystal structures for the M 2 and M 3 muscarinic receptor subtypes (Haga et al., 2012; Kruse et al., 2012 ) enables a structure-based discovery program for novel muscarinic ligands. To discover new chemotypes and compounds with novel physical and pharmacologic properties, we initially docked large compound libraries against the M 2 muscarinic structure. A high discovery rate of new chemotypes and new physical properties inspired us to seek M 3 -selective molecules by exploiting the small region of sequence difference between the two receptor subtypes. Whereas most molecules displayed some selectivity for the M 3 subtype, as designed in the docking screen, this selectivity was modest, illustrating the challenges of discovering subtype-selective orthosteric muscarinic ligands. However, the discovery of a partial M 3 agonist that had no agonist activity at the M 2 receptor, and its efficacy in a cell-based model to promote insulin release in b cells, also illustrates the potential of this approach.
Materials and Methods
Compounds were obtained from the vendors Molport (Riga, Latvia), Chembridge (San Diego, CA), Enamine (Kiev, Ukraine), Scientific Exchange (Center Ossipee, NH), Princeton Biomolecular Research (Princeton, NJ), and Asinex (Moscow, Russia), as well as from the Developmental Therapeutics Program at the National Institutes of Health National Cancer Institute. All compounds were sourced at 95% or greater purity as described by the vendors. All active compounds were further tested for purity by liquid chromatography-mass spectrometry at University of California at San Francisco, and were found to be at least 95% pure as judged by peak height and identity. For compounds 11 [(2S)-oxolan-2-ylmethyl 2-hydroxy-2,2-diphenylacetate] and 12 (benzyl2-hydroxy-2,2-diphenylacetate), liquid chromatography-mass spectrometry was inconclusive and purity was confirmed by 1 H-NMR spectroscopy at the Stanford Magnetic Resonance Laboratory using a Varian Inova 600 mHz spectrometer (Varian, Palo Alto, CA). Compound 5 was not commercially available in sufficient purity, and details regarding its preparation are given below.
Chemistry. Compound 5 (pyridin-3-ylmethyl 2-hydroxy-2,2-diphenyl acetate) was not commercially available in sufficient purity, and was synthesized as follows. After stirring a suspension of 3-(hydroxymethyl) pyridine (30 ml, 0.31 mM) and K 2 CO 3 (100 mg, 0.72 mM) in anhydrous dimethylformamide (12 ml) at room temperature for 1 hour, a solution of methyl benzilate (50 mg, 0.21 mM) in anhydrous dimethylformamide (3 ml) was added. The mixture was stirred at 65°C at 70-100 mbar for 6 hours and allowed to cool to room temperature. After addition of CH 2 Cl 2 and water, the organic layer was washed with a saturated aqueous solution of NaCl, dried (Na 2 SO 4 ), and evaporated. The residue was purified by flash chromatography (CH 2 Cl 2 -MeOH 60:1) to yield pure pyridin-3-ylmethyl 2-hydroxy-2,2-diphenylacetate (24.3 mg, 36%) as a white solid (melting point: 98-101°C 174.3, 149.3, 148.8, 141.7, 136.6, 131.1, 128.4, 128.3, 127.5, 123.9, 81.4, 65.7; IR (NaCl) (Lorber and Shoichet, 2005; Irwin et al., 2009; Mysinger and Shoichet, 2010) to virtually screen the approximately 3.1 million lead-like and fragment-like subsets of ZINC (Irwin and Shoichet, 2005; Irwin et al., 2012) against the M 2 or M 3 muscarinic receptor structure. Compounds were docked in multiple orientations and multiple conformations. Each geometry was scored for electrostatic and van der Waals complementarity, and corrected for desolvation using the solvent-excluded volume method, and the complex with the lowest energy was picked. Compounds were manually selected for experimental testing from the top-ranking 500 molecules based both on their physical complementarity and chemical novelty, using criteria previously described .
To identify compounds that selectively bind to the M 3 receptor, a similar method was first employed to score lead-like and fragmentlike subsets of ZINC against both receptors. The top 5000 ranked molecules against the M 3 receptor were selected for further consideration. Each of these molecules was then ranked according to the difference in energy score between docking at M 3 and M 2 . The 500 molecules with the largest energy score difference in favor of the M 3 receptor were then inspected, and 16 were chosen for experimental testing on the basis of high physical and chemical complementarity to M 3 , poor complementarity to M 2 , and novelty.
Receptor Expression and Membrane Preparation. Human M 2 and rat M 3 muscarinic receptors were expressed with an aminoterminal FLAG epitope tag in Sf9 insect cells using the BestBac system (Expression Systems, Davis, CA). Membranes were prepared using a glass dounce tissue grinder to homogenize cells in 20 mM Tris pH 7.5 and 1 mM EDTA. Homogenized cell material was then centrifuged at low speed (100g) for 5 minutes to remove debris. The supernatant was then centrifuged at 18,000g in an SA-800 rotor for 15 minutes to pellet membranes. Membranes were resuspended in binding buffer (75 mM Tris, pH 7.4, 12.5 mM MgCl 2 , 1 mM EDTA), aliquoted, and flash frozen in liquid nitrogen.
Radioligand Binding Assays. Ligand affinities were measured by radioligand displacement binding assays. Binding assays were performed using 3 H-N-methyl scopolamine (NMS; PerkinElmer, Waltham, MA) at 0.61 nM in all samples. Following mixing of membranes, cold ligand and NMS samples were shaken at 20°C for 2 hours. Samples were then filtered on a glass fiber filter with a 48-well harvester (Brandel, Gaithersburg, MD). Radioactivity was measured by liquid scintillation. Binding data are summarized in Tables 1 and 2, ) (a Ga q subunit in which the last five amino acids were replaced with the corresponding Ga i sequence) were incubated with increasing concentrations of ligands, and changes in intracellular calcium levels were determined using fluorometric imaging plate reader technology (Molecular Devices, Sunnyvale, CA). All measurements were performed in 96-well plates, as described previously (Li et al., 2007; McMillin et al., 2011) . Agonist concentration-response curves were analyzed using GraphPad Prism 4.0 software.
cAMP Assay. CHO cells stably expressing the human M 2 receptor were trypsinized, collected by centrifugation, and resuspended in phosphate-buffered saline containing glucose (1 mg/ml) and EDTA-free complete protease inhibitor (Roche Applied Science, Basel, Switzerland) at a density of 1 Â 10 6 cells/ml. Subsequently, 20-ml aliquots were added to 200-ml polymerase chain reaction tubes and incubated with the same volume (20 ml) of increasing concentrations of ligands in the presence of 50 mM forskolin for 25 minutes at 37°C. The incubation mixtures were then transferred into white-bottom 384-well plates (∼5000 cells/well), and cells were lysed to determine drug-dependent changes in cAMP levels using a fluorescence resonance energy transfer-based cAMP detection technique (cAMP dynamic 2 kit; Cisbio Bioassays, Bedford, MA) according to the manufacturer's protocol. An elevated 665/620 nm ratio indicates decreased cAMP levels in this assay.
Insulin Release Assays (MIN6 Cells). MIN6 cells (a kind gift from Dr. Abner Notkins, National Institute of Dental and Craniofacial Research, National Institutes of Health) were cultured as described previously (Ishihara et al., 1993) . 60,000 cells were seeded into 96-well plates and cultured for 48 hours at 37°C in 5% CO 2 . After this time, MIN6 cells were washed with 3.3 mM glucose buffer (in KrebsRinger bicarbonate/HEPES buffer) and then incubated for 1 hour at 37°C in 5% CO 2 . After this step, MIN6 cells were incubated for another hour at 37°C in 5% CO 2 with increasing concentrations of oxotremorine-M (OXO-M) or compound 16 [1-(3,5-dichlorobenzenesulfonyl)-4-methylpiperazine] in 16.7 mM glucose Krebs-Ringer buffer. Insulin release was determined by measuring insulin concentrations in the incubation medium using an insulin enzyme-linked immunosorbent assay kit (Crystal Chem, Inc., Downers Grove, IL). To confirm that the observed responses were mediated by muscarinic receptors, some assays were carried out in the presence of atropine (10 mM). E max and EC 50 values were obtained from OXO-M and compound 16 concentrationresponse curves using GraphPad Prism 4.0 software.
Antagonism Assay. To examine whether compounds 12, 13 [3-(4,6-dimethyl-1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-isoindol-2-yl)-N,N,Ntrimethyl-1-propanaminium iodide], and 20 [1-(2-{[4-(4-methoxyphenyl) oxan-4-yl]formamido}ethyl)-2-methyl-1H-imidazol-3-ium] were able to block M3 receptor-mediated responses, we determined their ability to inhibit OXO-M-induced increases in intracellular calcium levels via activation of M 3 receptors endogenously expressed by MIN6 cells. 50,000 cells were seeded into 96-well plates, and fluorometric imaging plate reader assays were carried out as described above (calcium mobilization assay). On the day of the assay, cells were preincubated with the calcium-chelating dye and the various compounds (atropine and compounds 12, 13, and 20) for 45 minutes, followed by the addition of the muscarinic receptor agonist OXO-M (1 mM). Compounds 12, 13, and 20 were used at a concentration of 10 mM (∼10 times their K i ). Atropine was employed at a concentration of 10 nM.
Results
Identification of New Muscarinic Ligands. To identify new muscarinic ligands and to assess the suitability of muscarinic receptor structures as templates for ligand discovery, we pursued a docking campaign against the M 2 muscarinic receptor structure. Like most GPCR structures available to date, the M 2 receptor was solved in an inactive conformation bound to a small molecule antagonist. It presents a deep, almost completely buried ligand-binding site (Fig. 1A) , covered by a layer of tyrosines long known to be critical for ligand binding. Such deeply buried cavities are well-suited to computational ligand discovery, and previous GPCR docking work has met with remarkable success (Sabio et al., 2008; Kolb et al., 2009; Carlsson et al., 2010; Katritch et al., 2010; de Graaf et al., 2011; Costanzi et al., 2012; Mysinger et al., 2012) . Within the binding pocket, the crystallographic ligand quinuclidinyl benzilate (QNB) engages largely in hydrophobic interactions, while Asn404 6.52 forms a pair of hydrogen bonds, and Asp103 3.32 serves as a counter ion to the positive charge of the ligand (Fig. 1B; superscript numerals refer to the Ballesteros-Weinstein numbering system for GPCRs) (Ballesteros and Weinstein, 1995) .
We screened 3.1 million fragments or "lead-like" molecules (Materials and Methods) from the ZINC database (Irwin and Shoichet, 2005; Irwin et al., 2012) against the structure of the M 2 receptor. Each fragment and "lead-like" molecule was sampled in an average of 222 and 274 orientations and 437 and 700 conformations, respectively, in the orthosteric site; overall, over 547 billion configurations of the 3.1 million molecules were sampled. Molecules were ranked based on van der Waals and electrostatic complementarity and corrected for ligand desolvation using a receptor volume-based implementation of the Generalized-Born equation (Mysinger and Shoichet, 2010) . From among the top 500-ranked molecules, we selected 18 that interacted with key residues such as Asp103 3.32 , Asn404 6.52 , and Trp400 6.48 , preferring molecules topologically or physically dissimilar to known muscarinic ligands. These 18 molecules were tested by single point competition binding against the high affinity antagonist 3 H-NMS (Supplemental Table 1 ), and those with substantial inhibition at 20 mM were further tested in a competition binding assay. Of the 18 compounds tested, 11 had K i values lower than 50 mM (Supplemental Fig. 1 ; Supplemental Table 2 ; Table 1 ). The compound with the highest affinity (compound 1 [2-(2-benzhydryloxyethyl)isothiourea]) displayed a K i of 390 nM. Six of these compounds were fragments, with ligand efficiencies ranging from 0.36 to 0.44 kcal/heavy-atom. Most of the 11 molecules were topologically dissimilar to known muscarinic agents. Using two-dimensional ECFP4 fingerprints and Tanimoto coefficients (T c ) (Hert et al., 2004) to all known muscarinic ligands in ChEMBL11 (Gaulton et al., 2012) , 8 of the 11 compounds were found to have a T c , 0.33 to the closest muscarinic ligand of any class, a difference large enough to be typically considered a "scaffold hop" (Muchmore et al., 2008) . Correspondingly, their binding poses differ substantially from that of the cocrystallized ligand (Fig. 1C) .
Intriguingly, two of the higher affinity ligands, compounds 5 and 11 (Table 1) , lack the defining cationic amine that is ubiquitous among muscarinic ligands and other aminergic GPCRs (e.g., histaminergic, adrenergic, dopaminergic, or serotonergic). Indeed, they were chosen for testing because of this unexpected physical property. Whereas in compound 5 the pyridine nitrogen might conceivably be cationic-although it would be expected to be neutral at physiologic pH, and is docked in this form-compound 11 is constitutively neutral at all accessible pH values. Correspondingly, the phenyl analog of 5 and 11, compound 12, is also a ligand with low micromolar affinity. The loss of the Asp103 3.32 ion-pair with the ligand cation is a substantial insult, amounting to about 4 kcal/mol if one compares the affinity of compounds 11 and 12 to that of the analogous QNB, which binds with an affinity of 180 pM to the M 2 receptor (Heitz et al., 1999) . However, the fact that such ligands can even bind to muscarinic receptors at meaningful, reasonable concentrations has few precedents in the field (Barlow and Tubby, 1974) . Indeed, no uncharged ligands of the M 2 or M 3 receptors are reported in the ChEMBL database (i.e., all are expected to be ionized at physiologic pH values) of the over 5000 ligands annotated, and while four neutral analogs of acetylcholine and other acetic-acid esters are reported to be active at acetylcholine receptors of the guinea-pig ileum (Barlow and Tubby, 1974) , no further uncharged ligands have been reported subsequently, to the best of our knowledge. 
Structure-Based Ligand Discovery for Muscarinic Receptors
Docking for Subtype Selectivity. Though the docking against the M 2 receptor had no selectivity goal-compounds were simply chosen based on complementarity to the M 2 receptor-we were interested to learn whether the unusual chemotypes and physical properties of the new ligands conferred selectivity. We thus tested those M 2 ligands with K i values lower than 10 mM for binding to the M 3 receptor (Supplemental Fig. 2 ; Table 1 ) (those molecules with weaker affinity were not pursued). Intriguingly, all three uncharged ligands (5, 11, and 12) bear some selectivity for the M 3 over the M 2 subtype. For example, compound 12 shows a 5-fold higher affinity for the M 3 subtype (K i 5 290 nM) as compared with the M 2 subtype. Prompted by this observation, we explicitly set out to exploit the few differences that do exist between the M 2 and M 3 orthosteric sites in docking screens for subtype-selective ligands, treating the M 2 subtype as a docking "antitarget." In the M 3 receptor, M 2 Phe181 is replaced by a leucine, creating an enlarged pocket that might be exploited to achieve binding selectivity (Fig. 2, A and B) . We again docked the fragment and "lead-like" subsets of the ZINC database against both the M 2 and M 3 receptors, this time selecting the top-ranked 5000 molecules against the M 3 receptor. From these compounds, we chose 500 molecules with the largest rank difference between subtypes ( Fig. 2C; Supplemental Fig.  3 ; Supplemental Table 3; Table 2 ). For instance, compound 13 ranks 2496 out of 3.1 million (top 0.1%) docked against the M 3 receptor, but ranks only 1,238,745 out of 3.1 million (top 40%) against the M 2 receptor, suggesting much better complementarity to the M 3 subtype. From these 500 molecules, 16 candidates were selected for testing, again weighing key interactions and chemical novelty (Table 2) . Of these candidates, eight compounds showed detectable binding to the M 3 receptor. We then tested each of these molecules for affinity against both receptor subtypes. Although most compounds showed detectably higher affinity for the M 3 receptor, the selectivity ratios were typically modest, reaching at best 6-fold ( Table 2 ). The one exception was compound 16, a ligand with an unprecedented sulfonamide core and a ECFP4-based T c value of only 0.3 to the closest known muscarinic ligand in ChEMBL (Gaulton et al., 2012) . This molecule proved to be a partial agonist at the M 3 receptor in a cell-based functional assay (5 mM EC 50 value) without detectable activity at the M 2 receptor (see below).
Efficacy of New Ligands. Most docking screens against inactive GPCR structures have discovered only antagonists (Kolb et al., 2009; Carlsson et al., 2010 Carlsson et al., , 2011 Katritch et al., 2010; de Graaf et al., 2011) , while a docking screening against the activated state of the b 2 -adrenergic receptor discovered only agonists (Weiss et al., 2013) . Thus far, the only exception to this pattern is the k-opioid receptor, where an inactive state was used as a template for the docking-based discovery of specific agonists (Negri et al., 2013) . We therefore investigated the efficacy of the new ligands against both M 2 and M 3 receptors, using a calcium mobilization assay to test for G protein activation. The M 2 receptor couples primarily to the G i class of G proteins, which mediate inhibition of adenylyl cyclase, while the M 3 receptor preferentially couples to G q/ , mediating hydrolysis of phospoinositide lipids and consequent elevation of intracellular calcium. For these assays, we used CHO cells stably expressing the human M 3 receptor or CHO cells stably coexpressing the human M 2 receptor and a hybrid G protein G qi 5, which consists of a Ga q subunit in which the last five amino acids were replaced with the corresponding Ga i sequence, allowing coupling to the M 2 receptor (Wess et al., 1997) . Almost all compounds tested were devoid of agonist activity on either receptor. Additional functional studies with representative compounds showed that the uncharged compound 12 antagonized oxotremorine-M-induced activation of M 3 receptors in cultured MIN6 cells, as did compounds 13 and 20 ( Supplemental Fig. 4) .
The only agent that showed agonist activity at the M 3 receptor was compound 16. This molecule was a partial agonist at the M 3 receptor, with an EC 50 of 5.2 mM an E max of 65%, but lacked detectable efficacy at the M 2 subtype (Fig. 3) . The lack of agonist activity of 16 at the M 2 receptor was confirmed in both calcium mobilization (Fig. 3A) and adenylate cyclase inhibition (Fig. 3B) assays. To our knowledge, compound 16 represents the first pharmacological agent that can activate M 3 but not M 2 receptors. This novel activity profile mirrors its unusual chemotype: unlike most muscarinic ligands, compound 16 cannot form a paired hydrogen bond with Asn 6.52 , as seen in the M 3 cocrystal structure with tiotropium, and instead may hydrogen bond through its unique sulfonamide to Tyr 3.33 (Fig. 3C) . Whether this configuration is conserved in the activated M 3 structure to which it must bind is uncertain at this time; we cannot now rule out the possibility that compound 16 may even bind in a completely unexpected manner, including even to allosteric pockets that may initiate activation in their own right (Bluml et al., 1994; Avlani et al., 2010; Gregory et al., 2010) . Further studies will be required to definitively establish the binding site for compound 16. For now, it is the novelty of this chemotype to which we attribute its unexpected activity and selectivity.
Compound 16 Stimulates Insulin Release in Pancreatic b Cells. The M 3 receptor is a critical regulator of acetylcholine-mediated glucose-dependent insulin release from pancreatic b cells, and recent studies indicate that increasing M 3 receptor signaling would be useful in the treatment of type 2 diabetes Ruiz de Azua et al., 2010) . However, further study of this concept has been stymied by the lack of selective M 3 agonists. We therefore tested the ability of compound 16, a selective M 3 agonist, to stimulate insulin release from pancreatic b cells. Specifically, we incubated MIN6 insulinoma cells, a mouse b-cell line expressing endogenous M 3 receptors, with increasing amounts of OXO-M, a potent muscarinic agonist, or compound 16. Both compounds evoked a dose-dependent increase in insulin secretion, with pEC 50 values of 24.21 and 25.75, respectively, for compound 16 and OXO-M. Compound 16 induced insulin secretion with an E max 58% that of OXO-M (Fig. 4) . Insulin release could be blocked by 10 mM atropine (Fig. 4B) , confirming the involvement of M 3 receptors.
Discussion
Four major observations emerge from this study. First, docking to the M 2 and M 3 muscarinic receptors led to the identification of multiple compounds with new physical properties and new chemical scaffolds. Second, as observed for other GPCRs, the docking hit-rates were high, between 50 and 60% of the compounds tested were active, with lead-like molecules often having affinities in the 0.1-1.0 mM range and with fragments with ligand efficiencies often above 0.4 kcal/ heavy-atom (de Graaf et al., 2011) . Third, an effort to explicitly dock for molecules specific for the M 3 over the M 2 subtype largely failed to successfully exploit the admittedly small difference between the two orthosteric sites, likely reflecting weaknesses in our current rigid-receptor docking models. Fourth, whereas it is not clear that the discovery of compound 16 reflects on our ability to select against binding to the M 2 subtype-it may simply reflect the unexplored functionality of this compound-compound 16 represents an important novel pharmacologic tool in that it can activate M 3 but not M 2 receptors. These findings hint at the potential of a structurebased program to discover compounds with new chemistry and correspondingly new pharmacology. 
Structure-Based Ligand Discovery for Muscarinic Receptors
A promise of structure-based discovery is the identification of molecules that physically complement a binding site but escape from trends emerging from classic structure-activity relationships. The muscarinic ligands are a good example of how a few key chemotypes and physical properties have come to dominate an area of pharmacology. Of over 5000 M 2 or M 3 receptor ligands annotated in ChEMBL, all bear at least a single cationic nitrogen. The discovery of ligands that are constitutively uncharged demonstrates that orthosteric site binding in muscarinic receptors is not contingent on the presence of such a cationic group. Since both cationic and uncharged ligands were found in our screen, and ranked about equally in the docking screen, this discovery also attests to the ability of a physics-based docking scoring function to balance high-magnitude ionic interactions (favoring charged ligands) and desolvation (favoring uncharged ligands) to arrive at a list of uncharged and cationic candidates. The uncharged ligands may balance the loss of the energy contributed by the Asp 3.32 ion pair by hydrogen bonds with Asn 6.52
and quadrupolar stacking with Tyr 6.51 and Trp 6.48 , as observed in the docked poses (Fig. 1) . These interactions are less common among cationic docking hits, which tend to be dominated by the Asp 3.32 interaction (Fig. 1) . Whereas the uncharged ligands bind as well as the new cationic ligands discovered here, they do lose about 4.5 kcal/mol in affinity compared with a structurally similar cationic ligand such as QNB, attesting to the importance of the ion-pair in contributing to high-affinity ligand binding. Still, as uncharged ligands will typically exhibit much greater membrane permeability than charged counterparts, such agents may show unique properties in vivo and may merit further exploration.
While the promise of discovering ligands with new chemotypes and new physical properties was realized in the docking screens, that of targeting particular differences between the M 2 and M 3 receptors to identify subtype-selective ligands was not. Although docking found molecules that fit much better against the rigid M 3 than the M 2 receptor structure owing to clashes with the larger Phe181 of the M 2 site, these apparent structural specificities largely disappeared on pharmacologic testing. Despite much more favorable M 3 docking ranks and scores (Table 2) , experimental preference for the M 3 subtype never rose above 6-fold in binding affinity. Thus, the steric clashes with Phe181 in the M 2 site were not realized, or only to a small degree, presumably reflecting conformational flexibility in the site. This has largely been true of other recent efforts to find molecules selective among different GPCR subtypes: where selective molecules have been found directly from docking, they may reflect more on the chemical novelty of the compounds than on specific interactions captured by the modeling (Carlsson et al., 2011; de Graaf et al., 2011; Kolb et al., 2012) . The exception to this is where chemical synthesis of multiple analogs, guided by structure, has followed initial hit-discovery by virtual screening (Langmead et al., 2012) . Whereas there are now several methods that allow one to model local receptor flexibility in docking (Durrant and McCammon, 2010; Henzler and Rarey, 2011) , implementing these prospectively in a way that does not lead to the appearance or even dominance of nonbinding decoys remains an ongoing challenge (Wei et al., 2004; Totrov and Abagyan, 2008) . As the structures of more receptor subtypes are being solved or become amenable to homology modeling, the call for reliable methods that can exploit small differences in receptor structure among closely related subtypes will become increasingly pressing. Correspondingly, the call for strategies that exploit differences among allosteric sites, which are often substantially greater than those between the orthosteric sites of receptor subtypes (May et al., 2007; Conn et al., 2009a) is also supported by this study. In all such efforts, a close collaboration with medicinal chemistry will be crucial, as molecules that are at once new to a receptor and optimal for it are unlikely to be present in any library of available molecules. The responses to both agonists were sensitive to blockade by atropine, indicating that the observed effects result from direct M 3 receptor activation. Data (mean 6 S.E.) are from three independent experiments: OXO-M pEC 50 = 5.75 6 0.17; E max = 453 6 21; compound 16 pEC 50 = 4.21 6 0.18; E max = 261 6 21. Atr, atropine; comp, compound. **P , 0.0092; ***P , 0.0001.
